Camsing Healthcare (BAC) H2 2025 earnings summary

Executive summary

• FY2025 revenue was S$4.783m, down S$69k YoY; loss before tax narrowed to S$2.302m from S$2.723m, while operating cash flow turned negative.

• Performance included S$1.869m of other income, mainly from waived loans and interest, payables written back and an interest unwind.

Financial highlights

• Revenue S$4.783m vs S$4.852m in FY2024; gross profit S$2.739m vs S$2.982m.

• Loss before tax and net loss were both S$2.302m, compared with S$2.723m in FY2024; FY2025 had no income tax credit.

• Marketing and distribution expenses rose to S$3.374m from S$3.248m; general and administrative expenses rose to S$1.954m from S$1.716m.

• Finance costs fell to S$322k from S$607k, mainly due to lower borrowings and waived loan interest.

• Operating cash flow was an outflow of S$1.392m vs an inflow of S$331k; investing outflow was S$194k and financing inflow was S$1.601m.

Outlook and guidance

• Uncertain global conditions and potential supply-chain disruption may weigh on consumer sentiment in coming quarters; priorities include new products, additional sales channels and prudent cost management.

• Retail portfolio reorganization began in the latest quarter, closing loss-making outlets and expanding online; performance was described as cautiously expected to improve, barring unforeseen circumstances.